Hair Loss Treatments for Menopause,
Ranked by Evidence

The benchmark. A 48-week randomized, double-blind, placebo-controlled trial of 381 women showed 5% topical minoxidil was superior to placebo on all three primary efficacy endpoints — hair count, patient assessment, and investigator assessment. The 5% formulation outperformed 2% on patient-reported outcomes. (Lucky et al., JAAD, 2004)

Minoxidil does not block DHT. It works downstream of the hormonal cascade by stimulating potassium channels in the follicle, increasing blood flow, and prolonging the anagen phase. This means it addresses symptoms (follicle underperformance) rather than root cause (androgen-driven miniaturization) — which is why it works best in combination with something that does target the hormonal driver.

Practical notes: The 5% foam (approved 2014) requires once-daily application and avoids the propylene glycol in the solution that causes scalp irritation in some women. Shedding in the first 2–8 weeks is common and indicates the treatment is working — it accelerates the transition of resting hairs to make room for new growth. Results reverse within 3–6 months of stopping.

Spironolactone is an anti-androgen that blocks androgen receptors in the hair follicle and reduces androgen production. It targets Step 3 of the cascade directly — preventing DHT from binding to receptors in the dermal papilla. In a prospective study, 86.5% of women using minoxidil plus oral spironolactone showed improvement at 24 weeks, compared to 55.3% using minoxidil alone. (Liang et al., Front Med, 2022)

Typical dosing for hair loss is 100–200 mg/day. Side effects may include potassium elevation, breast tenderness, and irregular periods (less relevant in postmenopausal women). Contraindicated in pregnancy. Requires periodic monitoring of potassium levels.

Practical notes: Slower onset than minoxidil — often 6–12 months before visible improvement. The real value is as a maintenance agent: spironolactone addresses the hormonal driver while minoxidil stimulates growth. Together, they cover both cause and symptom.

The only hair supplement with a published double-blind, randomized, placebo-controlled trial specifically enrolling perimenopausal, menopausal, and postmenopausal women (n=70, ages 40–65). At 6 months, the active group showed progressive increases in terminal, vellus, and total hair counts compared to placebo, with significantly less shedding and blinded-physician-confirmed improvement. A 12-month follow-up showed continued improvement, with a 13.4% increase in terminal hairs. (Ablon, JDD, 2021; Ablon et al., JDD, 2022)

The formulation targets multiple cascade steps simultaneously: saw palmetto for 5-alpha reductase inhibition (Step 3), Sensoril ashwagandha for cortisol regulation (stress-driven shedding), maca for hormonal support, and curcumin for inflammation. This multi-pathway approach is designed specifically for the hormonal complexity of menopause.

Why “Moderate” and not “Strong”: The trial was industry-funded with a relatively small sample size. The evidence is real and published in a peer-reviewed journal, but it does not yet match the depth of data behind minoxidil (multiple large independent trials) or spironolactone (decades of dermatologic use). That said, no other supplement has any comparable published data in menopausal women.

HRT addresses the first two steps of the cascade by restoring estrogen and progesterone. This rebuilds the protective buffers that keep DHT in check — estrogen restores aromatase activity, progesterone re-inhibits 5-alpha reductase. Some observational data suggests improved hair density in women on systemic HRT, particularly transdermal estradiol combined with micronized progesterone.

However, HRT was not designed as a hair loss treatment. Evidence for hair-specific outcomes is primarily observational, not from controlled trials targeting hair as a primary endpoint. Women already on HRT for vasomotor symptoms may see a secondary hair benefit, but initiating HRT solely for hair loss is not standard practice.

Practical notes: HRT candidacy depends on age, time since menopause, cardiovascular risk, and breast cancer history. It is a systemic treatment with systemic benefits and risks. If you are a candidate for HRT and also experiencing hair loss, the hormonal restoration may support your hair strategy — but it is unlikely to be sufficient as a standalone hair treatment for established pattern loss.

A 2025 systematic review and meta-analysis of 2,933 patients across 27 studies confirmed that low-dose oral minoxidil (typically 0.5–2.5 mg for women) is both safe and effective for treating hair loss. Among participants, 35% experienced significant improvement and 47% showed improvement. A separate 2024 randomized controlled trial found no significant difference in efficacy between 1 mg oral minoxidil and 5% topical minoxidil. An international expert consensus panel published guidelines in JAMA Dermatology (January 2025) endorsing clinical use. (Liu et al., Front Pharmacol, 2025; Penha et al., 2024)

The compliance advantage: One pill daily versus twice-daily topical application. For women who struggle with the scalp application routine or experience irritation from topical formulations, oral minoxidil may be the difference between consistent use and abandonment.

Caveats: Off-label use. The most common side effect is hypertrichosis (unwanted body hair growth), reported in about 35% of patients. A 2025 meta-analysis confirmed that low-dose oral minoxidil does not significantly affect blood pressure, addressing a major safety concern. Requires prescription and medical supervision.

LLLT uses red light (typically 650–670 nm wavelength) to stimulate cellular metabolism in hair follicles, promoting anagen entry and increasing hair density. Several devices (caps, helmets, combs) are FDA-cleared for both men and women. A 2024 randomized controlled trial found that combining LLLT with 2% minoxidil was comparable to minoxidil alone in women with female pattern hair loss. (Yang et al., Photodign Photodyn Ther, 2024)

Practical notes: Non-invasive, no side effects, no drug interactions. The main barriers are cost (devices range from $200 to $900) and compliance (most protocols require 3–4 sessions per week of 15–30 minutes). Works best as an adjunct to medical therapy, not a standalone.

PRP involves drawing a patient’s blood, concentrating the platelets, and injecting the growth-factor-rich plasma into the scalp. A 2025 randomized trial found that PRP and the combination of PRP plus minoxidil both produced significant improvement in hair count, density, and anagen ratio — with the combination showing the strongest results. (Koç Babayığit et al., J Dermatolog Treat, 2025)

Why “Emerging”: Results vary significantly between studies due to unstandardized preparation protocols (centrifuge speed, platelet concentration, injection depth). There is no FDA-approved PRP protocol for hair loss. Promising, but not yet reliable enough to rank alongside minoxidil or spironolactone.

Biotin (vitamin B7) is the most widely marketed hair supplement and the one with the least evidence for the specific context of menopause hair loss. There are no published randomized controlled trials demonstrating that biotin supplementation improves hair growth in women who are not biotin-deficient. Actual biotin deficiency is rare in adults eating a varied diet.

Biotin supplementation can also interfere with thyroid function tests and troponin assays, potentially causing false results — a meaningful concern for midlife women who need accurate lab monitoring.

The verdict: If your doctor confirms biotin deficiency, supplementation is reasonable. As a standalone treatment for menopause-related pattern hair loss, biotin has no published support. The $80/month you might spend on premium biotin gummies would be more effective directed toward minoxidil, a dermatology visit, or a supplement with actual published data in menopausal women.